Convalescent plasma treatment for SARS-CoV-2 infection

Heli Harvala¹ , Jennifer Mehew² , Matthew L Robb² , Samreen Ijaz³ , Steven Dicks^1,3 , Monika Patel⁴ , Nicholas Watkins⁵ , Peter Simmonds⁶ , Tim Brooks⁷ , Rachel Johnson² , Robin Gopal⁴ , David J Roberts^8,9 , Maria Zambon³ , the NHS Blood and Transplant Convalescent Plasma Testing Group¹⁰

Abstract: Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.28.2001260